Radius Health, Inc. (RDUS) Shares Sold by TIAA CREF Investment Management LLC

Radius Health, Inc. (RDUS) Shares Sold by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC cut its position in Radius Health, Inc. (NASDAQ:RDUS) by 2.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 106,832 shares of the biopharmaceutical company’s stock after selling 2,129 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.25% of Radius Health worth $5,779,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of RDUS. New York State Common Retirement Fund raised its stake in shares of Radius Health by 8.7% in the third quarter. New York State Common Retirement Fund now owns 100,757 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 8,084 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Radius Health by 5.5% in the third quarter. BlackRock Fund Advisors now owns 1,429,056 shares of the biopharmaceutical company’s stock worth $77,298,000 after buying an additional 74,854 shares in the last quarter. BlackRock Inc. raised its stake in shares of Radius Health by 10.3% in the third quarter. BlackRock Inc. now owns 3,145 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 293 shares in the last quarter. BlackRock Advisors LLC raised its stake in shares of Radius Health by 31.6% in the third quarter. BlackRock Advisors LLC now owns 36,175 shares of the biopharmaceutical company’s stock worth $1,957,000 after buying an additional 8,679 shares in the last quarter. Finally, DIAM Co. Ltd. bought a new stake in shares of Radius Health during the third quarter worth $170,000. 96.46% of the stock is owned by institutional investors.

Shares of Radius Health, Inc. (NASDAQ:RDUS) traded up 3.85% during midday trading on Friday, hitting $43.67. 549,485 shares of the company traded hands. Radius Health, Inc. has a 12-month low of $24.75 and a 12-month high of $59.88. The stock’s 50-day moving average is $41.92 and its 200 day moving average is $48.79. The stock’s market capitalization is $1.88 billion.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by $0.04. During the same period last year, the business posted ($0.68) EPS. On average, analysts expect that Radius Health, Inc. will post ($4.41) earnings per share for the current year.

A number of analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $85.00 price target on shares of Radius Health in a research note on Wednesday, December 21st. Finally, Cantor Fitzgerald set a $70.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Thursday, December 8th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Radius Health presently has a consensus rating of “Hold” and a consensus target price of $57.57.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).

Related posts

Leave a Comment